Candel Therapeutics, Inc. (CADL)
NASDAQ: CADL · Real-Time Price · USD
5.95
-1.01 (-14.46%)
At close: Mar 28, 2025, 4:00 PM
6.00
+0.05 (0.91%)
After-hours: Mar 28, 2025, 7:46 PM EDT

Candel Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2019
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019
Revenue
--0.130.130.13
Upgrade
Cost of Revenue
18.2323.5920.3514.59-
Upgrade
Gross Profit
-18.23-23.59-20.22-14.470.13
Upgrade
Selling, General & Admin
14.414.4114.511.265.99
Upgrade
Research & Development
----7.94
Upgrade
Operating Expenses
14.414.4114.511.2613.94
Upgrade
Operating Income
-32.63-38-34.72-25.73-13.81
Upgrade
Interest Expense
-2.09-2.6-1.71-0.05-
Upgrade
Interest & Investment Income
1.092.081.22-0.11
Upgrade
Other Non Operating Income (Expenses)
-20.80.9716.42-10.81-3.98
Upgrade
EBT Excluding Unusual Items
-54.44-37.55-18.79-36.59-17.68
Upgrade
Merger & Restructuring Charges
-0.7----
Upgrade
Asset Writedown
-0.04-0.39---
Upgrade
Other Unusual Items
---0.46-
Upgrade
Pretax Income
-55.18-37.94-18.79-36.12-17.68
Upgrade
Net Income
-55.18-37.94-18.79-36.12-17.68
Upgrade
Net Income to Common
-55.18-37.94-18.79-36.12-17.68
Upgrade
Shares Outstanding (Basic)
3229291912
Upgrade
Shares Outstanding (Diluted)
3229291912
Upgrade
Shares Change (YoY)
9.47%0.39%52.72%62.49%0.70%
Upgrade
EPS (Basic)
-1.74-1.31-0.65-1.91-1.52
Upgrade
EPS (Diluted)
-1.74-1.31-0.65-1.91-1.52
Upgrade
Free Cash Flow
-27.04-34.7-32.72-24.05-10.55
Upgrade
Free Cash Flow Per Share
-0.85-1.20-1.14-1.27-0.91
Upgrade
Gross Margin
----100.00%
Upgrade
Operating Margin
---27777.60%-20580.80%-11048.00%
Upgrade
Profit Margin
---15035.20%-28899.20%-14144.00%
Upgrade
Free Cash Flow Margin
---26172.80%-19242.40%-8437.60%
Upgrade
EBITDA
-31.64-37.04-33.94-25.49-13.72
Upgrade
D&A For EBITDA
0.990.960.780.230.09
Upgrade
EBIT
-32.63-38-34.72-25.73-13.81
Upgrade
Updated Mar 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q